THIRUVANANTHAPURAM: The Association of Medical and Paediatric Oncologists of Kerala (AMPOK) announced a research grant of Rs ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Alzheimer's disease (AD) is a debilitating neurodegenerative condition that affects a significant proportion of older people ...

Scientists in Australia have discovered that a magnetic brain treatment already used for depression can boost the brain’s ...

Drugs that treat a similar plasma cell disease, multiple myeloma, can sometimes be effective in people with AL amyloidosis. By far, the most important of these drugs is daratumumab (Darzalex), a ...

Elsie soon learned the cause - cardiac amyloidosis. "We used to think of it more as a rare disease," says Dr. Carly Fabrizio of Temple Health. But Dr. Fabrizio says heart failure specialists like ...

AS-Amyloidosis Consortium. Nitsche and colleagues looked at 226 patients (mean age 85 years; 80.4% male) with both moderate/severe AS and ATTR-CA who enrolled in the registry across 16 specialist ...

The current treatments for relapsed/refractory AL Amyloidosis typically yield less than a 10% complete response rate, highlighting a significant unmet medical need in this patient population.

BEYONTTRA is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with ...

The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research. About Immix Biopharma, Inc.